全谱内镜提高炎症性肠病患者不典型增生监测效果
该前瞻性随机交叉串联结肠镜研究在52例接受肿瘤监测的炎症性肠病患者中比较全谱内镜(FUSE)与常规前视结肠镜(FVC)对不典型增生的检出。FUSE较FVC显著降低不典型增生漏诊率并增加检出数量,但需更长退镜时间。
要点
- FUSE较FVC显著降低不典型增生漏诊率(病灶水平25.0% vs 71.4%)。
- FUSE检出不典型增生数量多于FVC(平均0.37 vs 0.13个)。
- FUSE退镜时间显著长于FVC(15.8 vs 12.0分钟)。
核心结论
- 在炎症性肠病监测结肠镜中,FUSE提供的全景视图较FVC增加不典型增生检出数量并降低漏诊率。
研究设计与样本
- 前瞻性、随机、交叉、串联结肠镜研究,纳入52例接受肿瘤监测的炎症性肠病患者(23例克罗恩结肠炎,29例溃疡性结肠炎;中位年龄45.0岁;男性60%;平均病程16.4年)。
- 27例随机分配至先FVC后FUSE组,25例分配至先FUSE后FVC组;所有操作于2014年2月至2015年12月进行。
主要发现
- 病灶水平漏诊率:FVC漏诊71.4%,FUSE漏诊25.0%(P = .0001)。
- 患者水平漏诊率:FVC漏诊75.0%,FUSE漏诊25.0%(P = .046)。
- FUSE平均检出0.37个不典型增生病灶,FVC平均检出0.13个(P = .044)。
- 总结肠镜时间相似(FUSE 21.2分钟 vs FVC 19.1分钟;P = .32),但FUSE退镜时间显著更长(15.8分钟 vs 12.0分钟;P = .03)。
- 校正每单位退镜时间后,FUSE每例患者平均不典型增生漏诊率显著低于FVC(0.19 vs 0.83;P < .0001)。
关键数值与推荐
- 所有受试者符合国家炎症性肠病监测纳入标准。
- 不典型增生由对结肠镜分配设盲的胃肠道病理专家与第二专家共识诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Inflammatory bowel diseases (IBDs) increase the risk of colorectal cancer. Surveillance colonoscopy with chromoendoscopy is recommended, but conventional forward-viewing colonoscopy (FVC) detects dysplasia with low levels of sensitivity. Full-spectrum endoscopy (FUSE) incorporates 2 additional lateral cameras to the forward camera of the colonoscope, allowing endoscopists to view behind folds and in blind spots, which might increase dysplasia detection. We compared FUSE vs FVC in the detection of dysplasia in patients with IBDs. METHODS: We performed a prospective, randomized, cross-over, tandem colonoscopy study comparing FVC vs FUSE in 52 subjects with IBD undergoing surveillance for neoplasia in Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age, 45.0 y; 60% male; mean IBD duration, 16.4 y). All subjects met national IBD surveillance inclusion criteria; 27 were assigned randomly to groups that underwent FVC followed by FUSE, and 25 were assigned to groups that underwent FUSE followed by FVC. All procedures were performed from February 2014 through December 2015. Random biopsy specimens were collected and visible lesions were collected; all were analyzed histologically. The primary end point was dysplasia missed by the first colonoscopy detected by the second colonoscopy. Dysplasia was diagnosed by an expert gastrointestinal pathologist blinded to the colonoscope allocation in consensus with a second expert pathologist. RESULTS: FVC missed 71.4% of dysplastic lesions per lesion whereas FUSE missed 25.0% per lesion (P = .0001); FVC missed 75.0% of dysplastic lesions per subject and FUSE missed 25.0% per subject (P = .046). FUSE identified a mean of 0.37 dysplastic lesions and FVC identified a mean of 0.13 dysplastic lesions (P = .044). The total colonoscopy times were similar (21.2 min for FUSE vs 19.1 min for FVC; P = .32), but withdrawal time was significantly longer for FUSE (15.8 min) than for FVC (12.0 min) (P = .03). Correcting for per-unit withdrawal time, the mean dysplasia miss rate per subject was significantly lower for FUSE (0.19) than for FVC (0.83; P < .0001). Targeted tissue acquisition identified significantly more dysplastic lesions than random biopsies (P < .0001). CONCLUSIONS: In a prospective cross-over study of IBD patients undergoing surveillance colonoscopy, we found panoramic views obtained by full-spectrum endoscopy increased the number of dysplastic lesions detected, compared with conventional forward-viewing colonoscopy. Trial no: ACTRN12616000047493.
引用
- Leong RW, Ooi M, Corte C, et al. Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017. PMID: 28126349. doi:10.1053/j.gastro.2017.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。